Protalix BioTherapeutics (PLX) Short-term Investments (2020 - 2026)

Protalix BioTherapeutics' Short-term Investments history runs 7 years deep, the most recent figure standing at $10.1 million for Q1 2026.

• In Q1 2026, Short-term Investments fell 34.04% year-over-year to $10.1 million; the TTM figure through Mar 2026 stood at $10.1 million (down 34.04% YoY), while the FY2025 annual figure was $15.6 million, up 3.47% from the prior year.
• Short-term Investments for Q1 2026 stood at $10.1 million, down from $15.6 million in the prior quarter.
• The five-year high for Short-term Investments was $21.6 million in Q2 2024, with the low at $5.1 million in Q4 2022.
• The 5-year median for Short-term Investments is $15.7 million (2025), against an average of $15.6 million.
• The sharpest annual moves came in 2022 and 2023: Short-term Investments tumbled 73.46% in 2022, then surged 312.82% in 2023.
• Protalix BioTherapeutics' Short-term Investments stood at $5.1 million in 2022, then surged by 312.82% to $20.9 million in 2023, then retreated by 27.98% to $15.1 million in 2024, then rose by 3.47% to $15.6 million in 2025, then plunged by 35.34% to $10.1 million in 2026.
• Business Quant data shows PLX's Short-term Investments at $10.1 million in Q1 2026, $15.6 million in Q4 2025, and $15.7 million in Q3 2025.